# Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/rfa-da-22-022-fentanyl-and-its-analogs-effects-and-consequences-for/  
Official notice: https://www.grants.gov/search-results-detail/335271

> National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 11, 2021.

| Field | Value |
|---|---|
| Opportunity number | RFA-DA-22-022 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | November 11, 2021 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.279 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

The purpose of this Funding Opportunity Announcement is to support research to understand and respond to new challenges in the treatment of drug addiction and overdose, introduced by the now widespread presence of fentanyl and its analogs (fentanils) in illicit drug supplies. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Applications may focus on the treatment of opioid and polydrug use disorders where fentanils are a major contributor to the problem. The research may include preclinical, clinical, epidemiological or post-mortem studies, but should have high impact and quickly yield the necessary information to understand and effectively respond to the impacts of fentanils in illicit drug supplies. Studies might also aim to develop new or repurposed medications or therapeutic devices or aim to revise therapeutic standards of care. Research dependent on development and implementation of toxicological assessment techniques required to identify and quantitate fentanils and their metabolites, and other opioids or abused substances in clinical and post mortem toxicological samples may also be appropriate if the aims are to understand the public health consequences and treatment of disorders associated with the knowing or unknowing consumption of fentanils. Research to develop new therapeutic medications, indications or devices should be designed to significantly advance the program towards FDA approval for the treatment of fentanil-related Substance Use Disorders or overdose.

## Questions people ask

### Is RFA-DA-22-022 still open?

No. It closed on November 11, 2021.

### Who can apply for Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional)?

Closed November 11, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-DA-22-022?

NIH RePORTER lists 7 projects funded under RFA-DA-22-022 in fiscal 2022 to 2026, at 4 institutions. The most were at Brown University, Rhode Island Hospital, Icahn School of Medicine at Mount Sinai.

### Who has won Drug Use and Addiction Research Programs grants before?

The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.